Completed OBSERVATIONAL NCT05363358

A Safety Study of GAMMAGARD LIQUID (GGL) in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Evaluating the Safety of GAMMAGARD LIQUID for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Sponsor: Baxalta Innovations GmbH, now part of Shire

Conditions Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Updated 5 times since 2022 Last updated: Apr 28, 2023 Started: May 27, 2022 Primary completion: Dec 1, 2022 Completion: Dec 1, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and is currently completed. Baxalta Innovations GmbH, now part of Shire leads this study, which shows 5 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jun 2023 — Jul 2024 [monthly]

Completed

Status: Active Not Recruiting → Completed
Jul 2022 — Jun 2023 [monthly]

Active Not Recruiting

Status: Not Yet Recruiting → Active Not Recruiting
Jun 2022 — Jul 2022 [monthly]

Not Yet Recruiting

First recorded

May 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Baxalta Innovations GmbH, now part of Shire
RTI Health Solutions
Takeda

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Durham, United States